Shopping Cart

Expired activity

Please go to the PowerPak homepage and select a course.

Faculty

Sandra Cuellar, PharmD, BCOP
Activity Chair
Clinical Oncology Pharmacist
Clinical Assistant Professor
Director, PGY-2 Oncology
University of Illinois Hospital and Health Sciences System
Chicago, Illinois

Rita Nanda, MD
Hematology and Oncology (Cancer)
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, Illinois

Needs Statement

Participants in this activity will gain insights into the molecular heterogeneity and diverse clinical features of triple-negative breast cancer (TNBC), which comprises 15%–20% of all breast cancer cases. Historically, TNBC has had limited treatment options and is associated with earlier age of onset, a more aggressive disease course, and a poorer prognosis than other breast cancers. This activity also will review the current state of immunotherapy research in TNBC, including completed and ongoing clinical trials across various stages of the disease continuum, the approval of emerging agents and indications throughout the treatment calculus, and prospective avenues of research focus, such as the identification of predictive novel biomarkers to help guide treatment decisions. Finally, using an interactive, case-based approach, this activity will comprehensively evaluate current clinical challenges in TNBC management and examine adaptive strategies that oncology pharmacists can employ to optimize patient outcomes in the era of immunotherapy.

Target Audience

This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.

Objectives

At the conclusion of this enduring activity, participants will be able to:

1. Discuss the molecular heterogeneity of triple-negative breast cancer (TNBC) and examine the diverse clinical features that impact treatment.
2. Appraise the current state of the TNBC treatment paradigm and investigate emerging, top-line trial data regarding the safety and efficacy profiles of immune checkpoint inhibitors.
3. Explore the importance of identifying novel biomarkers in TNBC to help guide treatment decisions.
4. Using a case-based approach, evaluate clinical challenges in TNBC management and discuss adaptive ways the oncology pharmacist can optimize patient outcomes in the era of immunotherapy.

Accreditation

CPE
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-013-H01-P).

Other
Creative Educational Concepts, Inc. certifies this activity for 1.0 hours of participation.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner
Bryan Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters
Sandra Cuellar, PharmD, BCOP—has disclosed that she is on the speakers’ bureau for Eisai and Genentech.

Rita Nanda, MD—has disclosed that she is a consultant for Aduro, Clovis, Daiichi Sankyo, Inc., Genentech, MacroGenics, Merck, and Pfizer. She receives grant/research support from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharm, Inc., Odonate Therapeutics, Pfizer, and Seattle Genetics. She receives financial support from G1 Therapeutics (DSMB).

Content Reviewer
Jason Bergsbaken, PharmD, BCOP—has no relevant financial relationships to disclose in relation to the content of this activity.

Activity Instructions

Media: Internet Web Activity (PowerPoint slides and audio)

Instructions

To receive a statement of credit, you must:

1. Read the target audience, learning objectives, and author disclosures.
2. Review the full content of the activity and reflect upon its teaching.
3. Complete the questions and evaluation at the end of the activity.
4. You must have a passing score of 75% on the post-test. You will have two (2) opportunities to complete the post-test.